Bempedoic Acid
Bempedoic Acid. Prodrug activated by very-long-chain-acyl-CoA synthetase (ACSVL1) — present only in liver, not skeletal muscle. Active form… Oral half-life 21 h.
Prodrug activated by very-long-chain-acyl-CoA synthetase (ACSVL1) — present only in liver, not skeletal muscle. Active form inhibits ATP-citrate lyase (upstream of HMG-CoA reductase in cholesterol synthesis). Liver-selective activation means no skeletal muscle exposure → no myalgia. CLEAR Outcomes trial 2023 showed MACE reduction as alternative for statin-intolerant patients.
PK: the one clean record in this batch — its citation is a real phase 1 study rather than an outcomes trial, and the half-life is corrected 21 -> 21.1 h, the figure that study states in healthy adults at steady state. The analyte is the parent prodrug in plasma. ka 1.01 /h, V 17.5 L and F 0.95 dropped as unsourced; the 3.5 h median beside the rate is a time to peak.
Pharmacokinetics
- Oral — t½ 21.1 h
Sources: PMID:36876740, PMID:37477389